SL
ACAD icon

Salomon & Ludwin’s Acadia Pharmaceuticals ACAD Stock Holding History

Salomon & Ludwin’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$34.6K Sell
1,375
-551
-29% -$12.1K ﹤0.01% 754
2026
Q1 		$42.8K Buy
1,926
+1,009
+110% +$24.1K ﹤0.01% 561
2025
Q4 		$24K Buy
917
+401
+78% +$9.58K ﹤0.01% 762
2025
Q3 		$11.2K Buy
+516
New +$12.2K ﹤0.01% 1221

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Salomon & Ludwin's ACAD Position: Q2 2026 in Review

Salomon & Ludwin reduced its Acadia Pharmaceuticals (ACAD) stake by 29% in Q2 2026, selling an estimated $12.1K and leaving 1,375 shares worth $34.6K. The position accounts for ﹤0.01% of the portfolio, ranked #754.

Salomon & Ludwin first reported a position in ACAD in Q3 2025 and has held it in 4 quarters since. The position peaked at $42.8K in Q1 2026. 353 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

  • Salomon & Ludwin held 1,375 shares of Acadia Pharmaceuticals worth $34.6K as of Q2 2026.
  • Salomon & Ludwin sold 551 Acadia Pharmaceuticals shares in Q2 2026, an estimated $12.1K.
  • Acadia Pharmaceuticals made up ﹤0.01% of Salomon & Ludwin's portfolio in Q2 2026, its #754 holding.
  • Salomon & Ludwin first reported a position in Acadia Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • Salomon & Ludwin's Acadia Pharmaceuticals position peaked at $42.8K in Q1 2026.
  • 353 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Salomon & Ludwin's 13F filing for Q2 2026, filed 7 Aug 2026.